Barcelona Alzheimer Treatment & Research Center

2014 54861911ALZ1005

DENOMINACIÓN: A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects with Prodromal Alzheimer’s Disease Investigating the Effects of JNJ-54861911 on Aβ Processing in CSF and Plasma
CÓDIGO DE PROTOCOLO: 54861911ALZ1005
PROMOTOR: JANSSEN
FASE: 1b
INDICACIÓN CLÍNICA: Mild Cognitive Impairment (MCI)
INICIO: 05/2014
FINAL: activo

Deja un comentario